Fulcrum Therapeutics News

Innovative Virtual Bench Solution for Enterprise Talent, Bench Talent Cloud, Announces Merger and Growth Funding

HR-tech startup, Fulcrum, has agreed to merge with Open Assembly's Future of Work consulting arm to create Bench Talent Cloud. Together, they are responsible for facilitating thousands of flexible wo

PR NewswireApr 2 09:32 ET

10 Health Care Stocks Whale Activity In Today's Session

Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.

BenzingaMar 29 13:35 ET

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives

GlobeNewswireMar 28 16:05 ET

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)

TipRanksMar 19 01:50 ET

Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer

Fulcrum Therapeutics (FULC) said Monday it appointed Patrick Horn as chief medical officer, effective immediately. Iain Fraser had been interim chief medical officer, and he will continue as senior vi

MT NewswiresMar 18 13:10 ET

Fulcrum Therapeutics: Horn Was Chief Medical Officer at Albireo Pharma >FULC

Fulcrum Therapeutics: Horn Was Chief Medical Officer at Albireo Pharma >FULC

Dow JonesMar 18 07:01 ET

Press Release: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer _Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to

Dow JonesMar 18 07:00 ET

Fulcrum Therapeutics: Interim Chief Medical Officer Iain Fraser Will Continue to Serve on Fulcrum's Executive Leadership Team as Senior Vice Pres of Early Development >FULC

Fulcrum Therapeutics: Interim Chief Medical Officer Iain Fraser Will Continue to Serve on Fulcrum's Executive Leadership Team as Senior Vice Pres of Early Development >FULC

Dow JonesMar 18 07:00 ET

Fulcrum Therapeutics Initiated at Outperform by RBC Capital

Fulcrum Therapeutics Initiated at Outperform by RBC Capital

Dow JonesMar 13 12:41 ET

Express News | RBC Capital Initiates Coverage On Fulcrum Therapeutics With Outperform Rating, Announces Price Target of $14

Moomoo 24/7Mar 13 12:31 ET

Fulcrum Therapeutics(FULC.US) Officer Sells US$57,218.5 in Common Stocks

$Fulcrum Therapeutics(FULC.US)$ Officer Tourangeau Greg sold 4,884 shares of Common Stocks on Mar 8, 2024 at an average price of $11.7155 for a total value of $57,218.5.Source: Announcement What is st

moomoo NewsMar 8 18:45 ET

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients

GlobeNewswireMar 8 16:30 ET

Fulcrum Hits 52-week High as CEO Buys Shares

Seeking AlphaMar 6 12:14 ET

Fulcrum Therapeutics(FULC.US) Officer Buys US$492.03K in Common Stocks

$Fulcrum Therapeutics(FULC.US)$ Officer Sapir Alex purchased 43,360 shares of Common Stocks on Mar 4, 2024 at an average price of $11.3475 for a total value of $492.03K.Source: Announcement What is st

moomoo NewsMar 5 17:00 ET

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to im

GlobeNewswireMar 5 08:00 ET

Strong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial Stability

TipRanksMar 1 01:04 ET

Fulcrum Therapeutics Full Year 2023 Earnings: Beats Expectations

Yahoo FinanceFeb 28 14:27 ET

Fulcrum Therapeutics Price Target Raised to $17.00/Share From $14.00 by HC Wainwright & Co.

Fulcrum Therapeutics Price Target Raised to $17.00/Share From $14.00 by HC Wainwright & Co.

Dow JonesFeb 28 13:23 ET

Fulcrum Therapeutics Is Maintained at Overweight by Piper Sandler

Fulcrum Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesFeb 28 10:54 ET

Express News | Piper Sandler Maintains Overweight on Fulcrum Therapeutics, Raises Price Target to $15

Moomoo 24/7Feb 28 10:44 ET